At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
CAT-354 150 mg (intravenous) +2 morebiological
Likely dose
CAT-354 150 mg (intravenous)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Parallel-Group, Bioavailability Study to Assess the Pharmacokinetics of CAT-354 Following Subcutaneous and Intravenous Administration
In Brief
A Phase 1 clinical trial evaluating CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), and 1 other intervention for Asthma and Healthy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
Study Details
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartApr 2008
Primary CompletionJun 2008
TodayJul 2026
First PostedMar 19, 2008
Enrollment StartApr 11, 2008
Primary CompletionJun 7, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.3 years ago
Interventions
CAT-354 150 mg (intravenous)biological
A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
CAT-354 150 mg (subcutaneous)biological
A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
CAT-354 300 mg (subcutaneous)biological
A single dose of CAT-354 300 mg injection subcutaneously on Day 0.